Pharmacological induction of a lipogenic program has been shown to antagonize TGF-β-driven myogenic differentiation, underscoring a potential therapeutic strategy for idiopathic pulmonary fibrosis (IPF) [36,37,38,39,40,41]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.